clinical trial · NCT07342881
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
Chronic Hepatitis B InfectionPevifoscorvir Sodium (ALG-000184)
brief summary
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
started
Feb 20, 2026
primary completion
Jun 15, 2026
completion
Jul 1, 2026
last updated
Feb 27, 2026
official title
A Phase 1 Non-Randomized, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol